Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants

23.05.2005


Amid the debate over which combination of immunosuppressive agents works best in helping patients fight off rejection of their new heart after transplant surgery, a new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ) had significant anti-rejection benefits for heart transplant patients over other combinations.



A mix of immunosuppressive therapies is typically used to prevent a recipient’s body from rejecting a transplanted organ. Rejection is one of the most common causes of death in the first year after heart transplantation.

"Until now, there has been a lack of definitive clinical trial data comparing commonly used immunosuppressive agents, and this has caused some debate over what is the most advantageous combination therapies for heart transplant recipients," said Dr. Jon Kobashigawa, lead author of the study and medical director of the UCLA Heart Transplant Program. "We now have results that demonstrate benefits in treating non-cellular and humoral rejection and this is significant step forward for heart transplant patients."


The study results, presented at the 6th American Transplant Congress in Seattle, involved more than 340 heart transplant recipients, and evaluated three combination therapies: 1) TAC + mycophenolate mofetil (MMF) and steroids, 2) cyclosporine microemulsion (CYA) + MMF and steroids, and 3) TAC + sirolimus (SRL) and steroids.

The primary purpose of this study was to compare the incidence of rejection requiring treatment, as measured by the International Society for Heart and Lung Transplantation (ISHLT) grading system.

Humoral rejection has been recently described in liver, kidney and heart transplant recipients by the National Institutes of Health (NIH) Consensus Conference. Humoral rejection is caused by the body making antibodies that can attack the donor organ, which is similar to the way that antibodies attack other foreign objects such as viruses or other infectious agents. This form of rejection can occur immediately (hyperacute rejection), or later after transplantation. The antibodies are either preformed antibodies (causing hyperacute rejection) or represent antibodies against the donor organ that developed after transplantation.

In heart transplant recipients, humoral rejection has been reported to play a role in the donor heart becoming weak in the early post-transplant period, and to be a risk factor for the development of transplant coronary artery disease, which is one of the major factors limiting long-term survival.

The study found no significant differences between treatment groups in survival or incidence of treated cellular rejection. Importantly, there was a significant reduction in any treated rejection in the TAC-treated groups. The category of any treated rejection included both cellular and humoral rejection. Therefore, these results suggested less humoral rejection in the TAC-treated groups.

The study also found that the TAC/MMF group had significantly better kidney function and lower triglycerides levels compared to the other two groups. Rates of post transplant diabetes were not significantly different. Fewer viral infections, but more fungal infections, were found in the TAC/SRL group.

The authors concluded that in heart transplant patients, TAC/MMF appeared to offer more advantages than either TAC/SRL or CYA/MMF, including the lowest incidence of any treated rejection and an improved side effect profile.

Other study authors included Dr. Leslie W. Miller, University of Minnesota, Minneapolis, MN; Dr. Stuart D. Russell, Johns Hopkins Hospital, Baltimore, MD; Dr. Gregory A. Ewald, Washington University, St. Louis, MO; Dr. Mark J. Zucker, Beth Israel Hospital, Newark, NJ; Dr. L. R. Goldberg, University of Pennsylvania, Philadelphia, PA; Dr. H. J. Eisen, Drexel University, Philadelphia, PA; Kim Salm, RN, D. Tolzman, W. E. Fitzsimmons, PharmD and Dr. M.R. First, Fujisawa Healthcare, Inc., Deerfield, IL; Dr. J. Gao, The EMMES Corporation, Rockville, MD.

Amy Waddell | EurekAlert!
Further information:
http://www.mednet.ucla.edu

More articles from Studies and Analyses:

nachricht Some brain tumors may respond to immunotherapy, new study suggests
11.12.2018 | Columbia University Irving Medical Center

nachricht Climate change and air pollution damaging health and causing millions of premature deaths
30.11.2018 | International Institute for Applied Systems Analysis (IIASA)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>